Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Buy

Analyst Rating

Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Buy

Wall Street Data Solutions Rating

Buy

A

Kiniksa Pharmaceuticals, Ltd. Class A Common Stock (KNSA)

Pharmaceutical Preparations

https://www.kiniksa.com

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404.

CLARENDON HOUSE, 2 CHURCH STREET
HAMILTON, D0

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

05/24/2018

Market Cap

1,855,186,339

Shares Outstanding

35,410,000

Weighted SO

70,338,354

Total Employees

N/A

Upcoming Earnings

07/23/2024

Similar Tickers

NUVL --.--%

VTYX --.--%

ACLX --.--%

CGEM --.--%

DAWN --.--%

GPCR --.--%

KRTX --.--%

PHAT --.--%

REPL --.--%

Beta

0.3760

Last Div

0.0000

Range

14.12-27.88

Chg

-0.1300

Avg Vol

474054

Mkt Cap

1855186339

Exch

NASDAQ

Country

BM

Phone

7814399100

DCF Diff

-13.3975

DCF

39.6575

Div Yield

0.0000

P/S

5.4737

EV Multiple

-67.0124

P/FV

4.2496

Div Yield %

0.0000

P/E

-180.7391

PEG

-5.8899

Payout

0.0000

Current Ratio

3.5712

Quick Ratio

3.1577

Cash Ratio

1.1777

DSO

22.0241

DIO

100.0635

Op Cycle

122.0875

DPO

21.2224

CCC

100.8652

Gross Margin

0.6248

Op Margin

-0.0812

Pretax Margin

-0.0532

Net Margin

-0.0302

Eff Tax Rate

0.4323

ROA

-0.0189

ROE

-0.0510

ROCE

-0.0600

NI/EBT

0.5677

EBT/EBIT

0.6552

EBIT/Rev

-0.0812

Debt Ratio

0.0210

D/E

0.0262

LT Debt/Cap

0.0210

Total Debt/Cap

0.0255

Int Coverage

-15.0136

CF/Debt

2.6720

Equity Multi

1.2467

Rec Turnover

16.5728

Pay Turnover

17.1988

Inv Turnover

3.6477

FA Turnover

27.3243

Asset Turnover

0.6248

OCF/Share

0.4291

FCF/Share

0.4269

Cash/Share

3.0809

OCF/Sales

0.0899

FCF/OCF

0.9949

CF Coverage

2.6720

ST Coverage

14.6120

CapEx Coverage

195.2949

Div&CapEx Cov

195.2949

P/BV

4.2496

P/B

4.2496

P/S

5.4737

P/E

-180.7391

P/FCF

61.2071

P/OCF

60.6893

P/CF

60.6893

PEG

-5.8899

P/S

5.4737

EV Multiple

-67.0124

P/FV

4.2496

DPS

0.0000

Latest Headlines (EST)

Zacks Investment Research Nov 24, 14:05 Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How Zacks Investment Research Nov 24, 14:05 Kiniksa Pharmaceuticals (KNSA) Up 14.7% YTD: Here's How GlobeNewswire Inc. Oct 31, 07:30 Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution

Revenue Product Segmentation